{
    "nctId": "NCT04472845",
    "briefTitle": "HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-risk Patients With Breast Cancer (HYPART).",
    "officialTitle": "HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-risk Patients With Breast Cancer (HYPART): A Non-inferiority, Open-label, Phase III Randomized Trial.",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Hypofractionation, Radiotherapy Side Effect",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 1018,
    "primaryOutcomeMeasure": "Loco-regional recurrence, Change is being assessed",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age \u226518 years\n2. Female or male\n3. Invasive carcinoma of the breast\n4. Breast conserving surgery(BCS) with axillary clearance or total mastectomy with axillary clearance(TMAC); (reconstruction allowed but not with implant; tissue expanders with distant metal ports are allowed)\n5. Concurrent trastuzumab and hormone therapy is allowed\n6. Axillary staging and/or dissection\n7. Complete microscopic excision of primary tumour\n8. pT3-4pN2-3 M0 disease\n9. Clinical stage III disease or pathological node positive if they have received neo-adjuvant chemotherapy.\n10. Written informed consent\n11. Able to comply with follow-up\n\nExclusion Criteria:\n\n1. Supraclavicular node or internal mammary node or distant metastasis\n2. Past history of malignancy except (i) basal cell skin cancer and CIN cervix uteri or(ii) non-breast malignancy allowed if treated with curative intent and at least 5 years disease free\n3. Contralateral breast cancer, including DCIS, irrespective of date of diagnosis\n4. Breast reconstruction using implants\n5. Pregnancy\n6. Concurrent cytotoxic chemotherapy(sequential neoadjuvant or adjuvant cytotoxic therapy allowed)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}